Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Supreme Court And Patents: What’s Not Happening

Jan 09 2017

• By Brenda Sandburg

US-Supreme-Court_V2_1200

Related Content

Angiomax Generics Imminent After Court Rules Patents Are Invalid

Jul 02 2015

Biosimilar Launch Notification: Solicitor General Backs Pre-FDA Approval Notice

Dec 09 2016

Angiomax Patents: Should Contract Manufacturing Count As Commercial Sale?

Mar 10 2016

Have Patent, Will Travel: Brand Firms Can File Infringement Suits Anywhere

Mar 19 2016

Mylan Wants Supreme Court To Limit Patent Litigation Venue

Sep 26 2016

Related Companies

Merck KGaA

Bayer AG

Viatris Inc.

Novartis AG

Amgen, Inc.

The Medicines Company

Hospira, Inc.

Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd.

Acorda Therapeutics, Inc.

AstraZeneca PLC

Additional Topics

United States Policy Intellectual Property Legal Issues BioPharmaceutical

More from Legal & IP

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window